SOURCE: Brighton Markets

February 06, 2012 09:00 ET

2012 Economic Outlook - Report Highlights Bed Bath & Beyond Inc. and Endo Pharmaceuticals

HONG KONG--(Marketwire - Feb 6, 2012) - Today, www.BrightonMarkets.com announced new reports highlighting Bed Bath & Beyond Inc. (NASDAQ: BBBY) and Endo Pharmaceuticals (NASDAQ: ENDP). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=BBBY&cob=ENDP.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Bed Bath & Beyond Inc. for its current position within the services industry. Bed Bath & Beyond Inc., along with its subsidiaries, is a chain of retail stores, operating under the names Bed Bath & Beyond (BBB), Christmas Tree Shops (CTS), Harmon and Harmon Face Values (Harmon) and buybuy BABY. In addition, the Company is a partner in a joint venture, which operates two stores in the Mexico City market under the name Home & More. The full research report on Bed Bath & Beyond Inc. (NASDAQ: BBBY) is available here: www.BrightonMarkets.com/index.php?coa=BBBY.

Brighton Markets has released research on Endo Pharmaceuticals for its changing role within the healthcare industry. Endo Pharmaceuticals Holdings Inc. (Endo) is a specialty healthcare solutions company focused on branded products and generics, and devices and services. The Company has a portfolio of branded pharmaceuticals, which includes brand names, such as Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar, and Supprelin LA. The full research report on Endo Pharmaceuticals (NASDAQ: ENDP) is available here: www.BrightonMarkets.com/index.php?cob=ENDP.

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.

Contact Information